Stevenage Bioscience Catalyst (SBC) is pleased to announce that Dr Wesley Randle is to join as Chief Business Officer (CBO) in June 2019.

Dr Randle joins from UCLB, the technology transfer company of UCL and its partner NHS Trusts where he was a Senior Business Manager. Whilst at UCLB he worked closely with the UCL Technology Fund and was responsible for managing the commercialisation of IP and technology at UCL Institute of Ophthalmology and Moorfields Eye Hospital.

Prior to joining UCLB, Wesley worked in a number of early stage companies including an Imperial College regenerative medicine spin-out and an Oxford University VC-backed ed-tech. He also has extensive experience in the support of innovation through his role as a University Innovation Directorand as an Enterprise Director at Colworth Science Park, a Unilever JV.

Wesley started his career as an industrial trainee with GSK PLC and has a degree in Biology, a PhD in Tissue Engineering and Regenerative Medicine, an MBA and is a Fellow of the Chartered Management Institute.

Dr Sally Ann Forsyth, CEO at SBC said: “With his excellent track record in IP commercialisation and development of start-ups both in the UK and overseas, Wesley is ideally placed to support the growing cluster of exciting companies here at SBC. We are delighted to welcome him to the team and look forward to working with him in the future."

Dr Wesley Randle, incoming CBO said: “I’m delighted to be working with Sally Ann again at such an exciting time for SBC. The Biotech, Pharma and Analytic industries are continuing to converge with the use of big data and tools to inform new product development, prevent and treat disease and make patients feel better and live longer.”